MedTrace Logo

Open Label Study of TRx0014 in Alzheimer's Disease

NCT00684944 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 111

Last updated 2018-04-27

No results posted yet for this study

Summary

This is an open label, dose-ranging study of two doses of TRx0014 in patients with mild or moderate Alzheimer's Disease. The trial is made available to any patient ongoing on treatment in the clinical trial designated TRx-014-001 at termination of that study. Treatment for each individual patient will continue for as long as the treating physician feels there is benefit to the patient. This current protocol covers each patient for 12 months in the first instance.

Conditions

Interventions

DRUG

TRx0014

Gelatin capsule, tid

Sponsors & Collaborators

  • TauRx Therapeutics Ltd

    lead INDUSTRY

Principal Investigators

  • Peter Bentham, MRCPsych · Queen Elizabeth Psychiatric Hospital, United Kingdom

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-09-13
Primary Completion
2010-12-02
Completion
2010-12-02
FDA Drug
Yes

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00684944 on ClinicalTrials.gov